Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Gastaminza

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Virus Research|July 29, 2017
Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replicationMairene Coto-Llerena, George Koutsoudakis, Loreto Boix, et al.
Antiviral Research|August 27, 2021
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular targetIsabel García-Dorival, Miguel Ángel Cuesta-Geijo, Lucía Barrado-Gil, et al.
Plos Pathogens|January 27, 2022
Guanosine inhibits hepatitis C virus replication and increases indel frequencies, associated with altered intracellular nucleotide poolsRosario Sabariegos, Ana María Ortega-Prieto, Luis Díaz-Martínez, et al.
Journal of Virology|March 10, 2017
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular EnvironmentElena Moreno, Isabel Gallego, Josep Gregori, et al.
Frontiers in Immunology|May 13, 2022
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than OmicronJosé M Casasnovas, Yago Margolles, María A Noriega, et al.
Nature Medicine|December 8, 2007
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challengeMansun Law, Toshiaki Maruyama, Jamie Lewis, et al.
International Journal of Molecular Sciences|April 12, 2022
Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport FunctionMaría Ángela Oliva, Carlota Tosat-Bitrián, Lucía Barrado-Gil, et al.
Frontiers in Immunology|December 6, 2021
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines ImmunogenicityCarlos Del Fresno, Juan García-Arriaza, Sarai Martínez-Cano, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Virus Research|July 29, 2017
Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replicationMairene Coto-Llerena, George Koutsoudakis, Loreto Boix, et al.
Antiviral Research|August 27, 2021
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular targetIsabel García-Dorival, Miguel Ángel Cuesta-Geijo, Lucía Barrado-Gil, et al.
Plos Pathogens|January 27, 2022
Guanosine inhibits hepatitis C virus replication and increases indel frequencies, associated with altered intracellular nucleotide poolsRosario Sabariegos, Ana María Ortega-Prieto, Luis Díaz-Martínez, et al.
Journal of Virology|March 10, 2017
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular EnvironmentElena Moreno, Isabel Gallego, Josep Gregori, et al.
Frontiers in Immunology|May 13, 2022
Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than OmicronJosé M Casasnovas, Yago Margolles, María A Noriega, et al.
Nature Medicine|December 8, 2007
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challengeMansun Law, Toshiaki Maruyama, Jamie Lewis, et al.
International Journal of Molecular Sciences|April 12, 2022
Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport FunctionMaría Ángela Oliva, Carlota Tosat-Bitrián, Lucía Barrado-Gil, et al.
Frontiers in Immunology|December 6, 2021
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines ImmunogenicityCarlos Del Fresno, Juan García-Arriaza, Sarai Martínez-Cano, et al.
Pageof 5